At the time of writing, Candel Therapeutics Inc [CADL] stock is trading at $5.0, up 2.15%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CADL shares have lost -14.09% over the last week, with a monthly amount drifted -16.11%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Candel Therapeutics Inc [NASDAQ: CADL] stock has seen the most recent analyst activity on September 03, 2025, when BofA Securities downgraded its rating to a Neutral but kept the price target unchanged to $7 for it. On February 20, 2025, Citigroup initiated with a Buy rating and assigned a price target of $25 on the stock. Canaccord Genuity started tracking the stock assigning a Buy rating and suggested a price target of $20 on February 19, 2025. BofA Securities initiated its recommendation with a Buy and recommended $15 as its price target on February 07, 2025. H.C. Wainwright started tracking with a Buy rating for this stock on December 02, 2022, and assigned it a price target of $11. In a note dated November 19, 2021, BMO Capital Markets initiated an Outperform rating and provided a target price of $18 on this stock.
For the past year, the stock price of Candel Therapeutics Inc fluctuated between $3.79 and $14.60. Candel Therapeutics Inc [NASDAQ: CADL] shares were valued at $5.0 at the most recent close of the market.
Analyzing the CADL fundamentals
Gross Profit Margin for this corporation currently stands at -0.98% with Operating Profit Margin at -36.2%, Pretax Profit Margin comes in at -22.14%, and Net Profit Margin reading is -22.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.41 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.87 points at the first support level, and at 4.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.09, and for the 2nd resistance point, it is at 5.18.
Ratios To Look Out For
It is important to note that Candel Therapeutics Inc [NASDAQ:CADL] has a current ratio of 7.04. As well, the Quick Ratio is 7.04, while the Cash Ratio is 6.84.
Transactions by insiders
Recent insider trading involved Nichols William Garrett, Chief Medical Officer, that happened on Jul 28 ’25 when 937.0 shares were sold. Chief Medical Officer, Nichols William Garrett completed a deal on Jun 30 ’25 to sell 781.0 shares. Meanwhile, Officer WILLIAM GARRETT NICHOLS bought 3593.0 shares on Jun 30 ’25.
